Table 1. The relationship between IL6R expression and clinical parameters in patients with LUAD in TCGA cohort.
| Variables | IL6R low (n=250) | IL6R high (n=250) | Total (n=500) | P value |
|---|---|---|---|---|
| Age (years), n (%) | ||||
| ≤65 | 125 (50.0) | 112 (44.8) | 237 (47.4) | |
| >65 | 122 (48.8) | 131 (52.4) | 253 (50.6) | |
| NA | 3 (1.2) | 7 (2.8) | 10 (2.0) | 0.268 |
| Gender, n (%) | ||||
| Female | 122 (48.8) | 148 (59.2) | 270 (54.0) | |
| Male | 128 (51.2) | 102 (40.8) | 230 (46.0) | 0.025 |
| Stage, n (%) | ||||
| I | 121 (48.4) | 147 (58.8) | 268 (53.6) | |
| II | 61 (24.4) | 58 (23.2) | 119 (23.8) | |
| III | 55 (22.0) | 25 (10.0) | 80 (16.0) | |
| IV | 10 (4.0) | 15 (6.0) | 25 (5.0) | |
| NA | 3 (1.2) | 5 (2.0) | 8 (1.6) | 0.003 |
| T, n (%) | ||||
| T1 | 70 (28.0) | 88 (35.2) | 158 (31.6) | |
| T2 | 125 (50.0) | 121 (48.4) | 246 (49.2) | |
| T3 | 25 (10.0) | 14 (5.6) | 39 (7.8) | |
| T4 | 8 (3.2) | 10 (4.0) | 18 (3.6) | |
| NA | 22 (8.8) | 17 (6.8) | 39 (7.8) | 0.193 |
| M, n (%) | ||||
| M0 | 155 (62) | 157 (62.8) | 312 (62.4) | |
| M1 | 10 (4.0) | 13 (5.2) | 23 (4.6) | |
| NA | 85 (34.0) | 80 (32.0) | 165 (33.0) | 0.757 |
| N, n (%) | ||||
| N0 | 142 (56.8) | 159 (63.6) | 301 (60.2) | |
| N1 | 40 (16.0) | 46 (18.4) | 86 (17.2) | |
| N2 | 43 (17.2) | 21 (8.4) | 64 (12.8) | |
| N3 | 2 (0.8) | 0 (0) | 2 (0.4) | |
| NA | 23 (9.2) | 24 (9.6) | 47 (9.4) | 0.019 |
IL6R, interleukin 6 receptor; LUAD, lung adenocarcinoma; TCGA, The Cancer Genome Atlas; NA, not applicable.